Sectors & IndustriesHealthcareBiotechnology

Best Biotech Stocks to Buy Now (2026)

Top biotech stocks in 2026 ranked by overall Zen Rating. "A" Rated stocks have returned an average of +32.52% per year, and are the best biotech stocks to buy now. Learn More.

According to Zen Ratings, our proprietary rating system that evaluates 115 factors proven to drive growth in stocks and assigns each stock in our system an overall letter grade as well as 7 individual Component Grades for Value, Growth, Momentum, Sentiment, Safety, Financials, and proprietary AI algorithms, the 3 best biotechnology stocks to buy right now are:

Jazz Pharmaceuticals (NASDAQ:JAZZ) is the #1 top biotech stock out of 605 with a Zen Rating of A. Stocks with a rating of A have had an average return of +32.52% per year. Learn more.

The Component Grade breakdown for Jazz Pharmaceuticals (NASDAQ:JAZZ) is: Value: A, Growth: A, Momentum: B, Sentiment: C, Safety: C, Financials: B, and AI: C.

Jazz Pharmaceuticals (NASDAQ:JAZZ) has a Due Diligence Score of 27, which is 2 points higher than the biotech industry average of 25.

JAZZ passed 9 out of 33 due diligence checks and has average fundamentals. Jazz Pharmaceuticals has seen its stock return 115.68% over the past year, overperforming other biotech stocks by 114 percentage points.

Jazz Pharmaceuticals has an average 1 year price target of $237.67, an upside of 3.89% from Jazz Pharmaceuticals's current stock price of $228.77.

Jazz Pharmaceuticals stock has a consensus Strong Buy recommendation according to Wall Street analysts. Of the 12 analysts covering Jazz Pharmaceuticals, 58.33% have issued a Strong Buy rating, 33.33% have issued a Buy, 8.33% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

Exelixis (NASDAQ:EXEL) is the #2 top biotech stock out of 605 with a Zen Rating of A. Stocks with a rating of A have had an average return of +32.52% per year. Learn more.

The Component Grade breakdown for Exelixis (NASDAQ:EXEL) is: Value: A, Growth: B, Momentum: C, Sentiment: B, Safety: C, Financials: A, and AI: C.

Exelixis (NASDAQ:EXEL) has a Due Diligence Score of 52, which is 27 points higher than the biotech industry average of 25.

EXEL passed 17 out of 33 due diligence checks and has strong fundamentals. Exelixis has seen its stock return 8.37% over the past year, overperforming other biotech stocks by 6 percentage points.

Exelixis has an average 1 year price target of $48.00, a downside of -4.25% from Exelixis's current stock price of $50.13.

Exelixis stock has a consensus Buy recommendation according to Wall Street analysts. Of the 7 analysts covering Exelixis, 14.29% have issued a Strong Buy rating, 14.29% have issued a Buy, 71.43% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

Protalix Biotherapeutics (NYSEMKT:PLX) is the #3 top biotech stock out of 605 with a Zen Rating of A. Stocks with a rating of A have had an average return of +32.52% per year. Learn more.

The Component Grade breakdown for Protalix Biotherapeutics (NYSEMKT:PLX) is: Value: A, Growth: B, Momentum: C, Sentiment: C, Safety: D, Financials: B, and AI: C.

Protalix Biotherapeutics (NYSEMKT:PLX) has a Due Diligence Score of 59, which is 34 points higher than the biotech industry average of 25.

PLX passed 19 out of 33 due diligence checks and has strong fundamentals. Protalix Biotherapeutics has seen its stock return 18.56% over the past year, overperforming other biotech stocks by 16 percentage points.

Protalix Biotherapeutics has an average 1 year price target of $12.00, an upside of 506.06% from Protalix Biotherapeutics's current stock price of $1.98.

Protalix Biotherapeutics stock has a consensus Buy recommendation according to Wall Street analysts. Of the 1 analyst covering Protalix Biotherapeutics, 0% have issued a Strong Buy rating, 100% have issued a Buy, 0% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

Out of 6 biotech stocks that have issued dividends in the past year, the 3 biotech stocks with the highest dividend yields are:

Dominari Holdings (NASDAQ:DOMH) has an annual dividend yield of 29.37%, which is 24 percentage points higher than the biotech industry average of 5.8%.

Dominari Holdings's dividend payout ratio of -19.1% indicates that its high dividend yield might not be sustainable for the long-term.

Oramed Pharmaceuticals (NASDAQ:ORMP) has an annual dividend yield of 5.39%, which is the same as the biotech industry average of 5.8%.

Oramed Pharmaceuticals's dividend payout ratio of 16.3% indicates that its high dividend yield is sustainable for the long-term.

Novo Nordisk (Ozempic) (NYSE:NVO) has an annual dividend yield of 2.85%, which is -3 percentage points lower than the biotech industry average of 5.8%. Novo Nordisk (Ozempic)'s dividend payout is not stable, having dropped more than 10% eight times in the last 10 years. Novo Nordisk (Ozempic)'s dividend has shown consistent growth over the last 10 years.

Novo Nordisk (Ozempic)'s dividend payout ratio of 43.1% indicates that its dividend yield is sustainable for the long-term.

Biotech stocks were down -2.85% in the last day, and down -1.74% over the last week. Dare Bioscience was the among the top losers in the biotechnology industry, dropping -24.13% yesterday.

Dare Bioscience shares are trading lower after the company reported worse-than-expected Q1 sales results.

Based on the Valuation rating, one of the 7 components of a stocks overall Zen Ratings grade, which evaluates factors including estimated earnings yield, earnings before interest and taxes/enterprise value, cash flow yield, free cash flow to price, and price-to-earnings growth (PEG ratio), the 3 most undervalued biotech stocks right now are:

Incyte (NASDAQ:INCY) is the most undervalued biotech stock based on its Valuation Rating of A. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Incyte has a valuation score of 71, which is 58 points higher than the biotech industry average of 13. It passed 5 out of 7 valuation due diligence checks.

Incyte's stock has gained 51.86% in the past year. It has overperformed other stocks in the biotech industry by 50 percentage points.

Rigel Pharmaceuticals (NASDAQ:RIGL) is the second most undervalued biotech stock based on its Valuation Rating of A. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Rigel Pharmaceuticals has a valuation score of 43, which is 30 points higher than the biotech industry average of 13. It passed 3 out of 7 valuation due diligence checks.

Rigel Pharmaceuticals's stock has gained 46.96% in the past year. It has overperformed other stocks in the biotech industry by 45 percentage points.

Harmony Biosciences Holdings (NASDAQ:HRMY) is the third most undervalued biotech stock based on its Valuation Rating of A. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Harmony Biosciences Holdings has a valuation score of 71, which is 58 points higher than the biotech industry average of 13. It passed 5 out of 7 valuation due diligence checks.

Harmony Biosciences Holdings's stock has dropped -12.09% in the past year. It has underperformed other stocks in the biotech industry by -14 percentage points.

65.8% of biotech stocks rated by analysts are a strong buy right now. On average, analysts expect biotech stocks to rise by 64.17% over the next year.

2.63% of biotech stocks have a Zen Rating of A (Strong Buy), 3.94% of biotech stocks are rated B (Buy), 45.73% are rated C (Hold), 37.64% are rated D (Sell), and 10.07% are rated F (Strong Sell).